...
首页> 外文期刊>Oncology letters >Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis
【24h】

Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis

机译:CHK1和P53在膀胱尿路上皮癌中的显着表达作为潜在的治疗目标和预后

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Checkpoint kinase 1 (CHK1) and p53 are involved in cell-cycle checkpoint, and cellular response to DNA damage. CHK1 and p53 are overexpressed in bladder urothelial carcinoma (BUC); however, a clear elucidation on their interaction and influence in the progress of BUC is absent. The aim of the present study was to examine the correlation between CHK1 and p53 in BUC, and analyze their value as therapeutic targets and prognostic indicators in BUC. A clinically annotated cohort of 110 patients with BUC was identified retrospectively. EnVision-based immunohistochemistry and western blot analysis of the aforementioned DNA repair proteins were conducted on formalin-fixed-paraffin-emb edded or frozen tissues from the primary tumor. A total of 45 peritumoral tissue cases were assessed similarly as the control group. In the cohort of 110 patients with BUC, a significant overexpression of CHK1 and p53 was observed in primary compared with the peritumoral tissues (P0.05). CHK1 and p53 demonstrated a positive correlation in BUC, and both were positively associated with the histological grade, clinical pathological staging, lymphatic metastasis and the 5-year survival rate (P0.05). However, CHK1 and p53 were not associated with sex, age, tumor diameter, single/multiple sites or incipient/recurrence. The overexpression of CHK1 and p53, and their synergistic interaction were putatively correlated with the physiology of BUC that may be deemed as potential therapeutic targets and prognostic indicators.
机译:检查点激酶1(CHK1)和P53参与细胞周期检查点,对DNA损伤的细胞响应。 CHK1和P53在膀胱尿路上皮癌(BUC)中过表达;然而,不存在对其相互作用和影响的清晰阐明。本研究的目的是检测BUC中CHK1和P53之间的相关性,并将其作为富集中的治疗靶标和预后指标分析。回顾性地鉴定了110例BUC患者的临床注释的110例。在来自原发性肿瘤的福尔马林固定石蜡-MB的ED或冷冻组织上对上述DNA修复蛋白进行了基于EMEL的免疫组织化学和Western印迹分析。与对照组相似评估共45例腹膜术病例。在110例BUC患者的群组中,与腹膜组织(P <0.05)相比,在初级观察到CHK1和P53的显着过表达。 CHK1和P53证明了BUC中的阳性相关性,两者均与组织学级,临床病理分期,淋巴结转移和5年生存率正相关(P <0.05)。然而,CHK1和P53与性别,年龄,肿瘤直径,单次/多个位点或初期/复发无关。 CHK1和P53的过表达及其协同相互作用与可以被视为潜在治疗靶标和预后指标的BUC的生理学相关。

著录项

  • 来源
    《Oncology letters》 |2018年第1期|共7页
  • 作者单位

    Zhejiang Canc Hosp Dept Pathol 1 East Rd Banshan Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Colorectal Surg Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Med Oncol 1 East Rd Banshan Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Pathol 1 East Rd Banshan Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Pathol 1 East Rd Banshan Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Pathol 1 East Rd Banshan Hangzhou 310022 Zhejiang Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    bladder urothelial carcinoma; CHK1; p53; therapy targets; prognosis;

    机译:膀胱尿路上皮癌;CHK1;p53;治疗目标;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号